key: cord-0740363-u2wo95sz authors: Re, D.; Seitz-Polski, b.; Carles, M.; Brglez, V.; Graca, D.; Benzaken, S.; Liguori, s.; Zahreddine, K.; Delforge, m.; Verriere, B.; Chamorey, E.; Barriere, J. title: Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies. date: 2021-07-22 journal: nan DOI: 10.1101/2021.07.18.21260669 sha: e6686e99ed4b76518c1ebcb1536ff00cfa099901 doc_id: 740363 cord_uid: u2wo95sz Humoral and cellular responses after a third dose of BNT162b2 vaccine in patients treated for lymphoid malignancies. BACKGROUND: Immunocompromised patients such as patients with hematological malignancies have impaired immune response to two doses of BNT162b2 (Pfizer / BioNtech) vaccine against SARS-CoV-2. Evaluation of a repeated immune stimulation with a third vaccine dose is needed. METHODS: a vaccine monitoring observatory was conducted in outpatients who were treated for lymphoid malignancies (LM) to monitor both immune and cellular response measured the day of administration of the dose 3 of the mRNA vaccine BNT162b2 and again three to four weeks. Elecsys Anti-SARS-CoV-2 immunoassay was used to asses to the level of SARS-CoV-2 anti-Spike (S) antibodies (Abs) titer and SARS-CoV-2-specific T-cell responses were assessed by a whole blood Interferon-Gamma Release Immuno Assay (IGRA) (QuantiFERON Human IFN-gamma SARS-CoV-2, Qiagen). RESULTS: Among the 43 assessable patients (suffering from chronic lymphocytic leukemia (CLL) (n=15), indolent and aggressive B cell non-Hodgkin lymphoma (NHL) (n=14), and multiple myeloma (MM) (n=16)), 18 (41,8%) had no anti-S Abs before the dose 3 of BNT162b2 vaccine (n=9 CLL, n=8 NHL, n=1 MM), and they all 18 remained negative after the dose 3. Amongst the 25 patients with positive anti-S titers before dose 3, all patients remained positive and 23 patients increased their anti-S titer after dose 3. Patients with CLL and/or with previous anti-CD20 therapy treated within 12 months of administration of dose 3 had no significant increase of the humoral response. Among 22 available patients, dose 3 of BNT162b2 vaccine significantly increased the median IFN-gamma secretion. On eight (36.4%) patients who were double-negative for both immune and cellular response, five (22.7%) patients remained double-negative after dose 3. CONCLUSIONS Dose 3 of BNT162b2 vaccine stimulated humoral immune response among patients with LM, in particular patients with MM (who had higher anti-S baseline titer after dose 2) and those with no anti-CD20 treatment history within a year. T-cell response was increased among patients in particular with no active chemotherapy regimen. Our data support the use of an early third vaccine dose among immunocompromised patients followed for LM though some of them will still have vaccine failure. in particular patients with MM (who had higher anti-S baseline titer after dose 2) and those with no anti-CD20 treatment history within a year. T-cell response was increased among patients in particular with no active chemotherapy regimen. Our data support the use of an early third vaccine dose among immunocompromised patients followed for LM though some of them will still have vaccine failure. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. induces high rates of seroconversion in a healthy population but is less effective in immunocompromised patients such as organ transplanted patients (3), patients treated for SC (4) (5) (6) or patients with HM (7-9). We and others showed previously that patients treated with anti-CD20 monoclonal antibodies (Mabs) prior to COVID-19 vaccination had a very low likelihood of developing a humoral response, especially if the anti-CD20 Mab treatment is performed within 6 to 12 months of administration of the anti-SARS-CoV-2 vaccine (8-9). Tcell response seemed more impaired in patients with HM than with SC, with a positive effect of the booster dose (6). We conducted a specific analysis of patients followed at our hospital for lymphoid malignancies (LM), who showed no or poor humoral response after vaccination with two doses of the mRNA vaccine BNT162b2 (Pfizer / BioNtech). We monitored their humoral and cellular response, after a third dose (dose 3) of BNT162b2 according to the recommendation of the French National Authority for health (10) published on April 11 th 2021. All participants signed a written informed consent and accepted their participation in this registered trial in accordance with ethical and legal French policies (Registration number F20210324145532). All data were prospectively collected on an electronic anonymous data set. These assays were a double-antigen sandwich electrochemiluminescence and were performed All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. All comparisons were two-tailed, and the differences were considered significant when P-value < 0.05. We analyzed a data set of 45 patients, prospectively included to receive dose 3 of the BNT162b2 vaccine given 78 days [range: 47-114] after dose 2 of the same vaccine. All 45 patients were negative for anti-N Abs before dose 3, but two patients were tested positive after dose 3 and were therefore excluded from the final analysis. Included patients were suffering from chronic lymphocytic leukemia (CLL) (n=15), indolent and aggressive B cell non-Hodgkin lymphoma (NHL) (n=14), and multiple myeloma (MM) (n=16). The median age of the 43 patients included in the final analysis was 77 years [range: 37-92], 63 % were men and 37 % women (Table 1 ). At the time of dose 3, patients' treatments are reported in Table 1 . Amongst 43 patients, 18 (41,8%) had no anti-S Abs before the dose 3 of BNT162b2 vaccine (n=9 CLL, n=8 NHL, n=1 MM), and they all 18 remained negative after the dose 3 (Table 1) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Fourteen of these 18 patients had already received an anti-CD20 Mab treatment, nine of them within the 12 months preceding the vaccine. One seronegative patient with MM was under active treatment for HIV infection. In univariate analysis, age and type of LM, but not sex or type of treatment (except for anti-CD20 Mab performed within 6 to 12 months of administration of the anti-SARS-CoV-2 vaccine), was statistically associated with anti-S response after dose 3 (Table 1) These patients included three cases of CLL (all actively treated with venetoclax and a past history of rituximab treatment) and two cases of NHL (rituximab and bendamustine, one on All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. We then compared the performance of serologic and IGRA testing using the method of the receiver operating characteristic (ROC) curve to explore the best way to detect a specific No novel adverse events were observed in our population after dose 3 of BNT162b2 vaccine. To our knowledge, this study is the first to report results on cellular and humoral immunity after Previous reports highlighted reduced rates of seroconversion after two doses of a SARS-CoV-2 vaccine for patients with HM, leaving some of them without detectable anti-S Ab protection All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.18.21260669 doi: medRxiv preprint (7-9), with lower response for patients with CLL, even without treatment, or patients under anti-CD20 therapy. We here showed that patients without Ab response after two doses do not benefit from a third dose of the same vaccine when the analysis is limited to serologic testing, thus eliminating the need of anti-S level measurement before and after a third vaccination in current clinical practice. The third vaccine dose increased the overall humoral response in those patients responding after the second dose, especially patients with MM, and to a lower extent patient with NHL, but not patients with CLL, suggesting a negative impact of the pathology on the induction of a specific T-cell response. Our study has some limitations, firstly due to the small number of included patients. Then, we were unable to measure the level of neutralizing Abs (availability and cost issues), preventing any correlation assessment of these Abs and the level of anti-S Abs. Finally, only a subgroup of the cohort has been evaluated for the cellular immunity, due to availability issues: a larger sample would have allowed more detailed subgroup analyzes, in particular according to the different treatments received. Considering the decrease of humoral immunity over time (18) , the known correlation between neutralizing Abs titers and clinical response (19) , and the here shown emergence of a specific cellular T-cell response, an early third dose of the SARS-CoV-2 vaccine seems necessary in patients with LM to allow optimal protection, even if anti-CD20 treated patients and patients treated with stem cell toxic drugs such as bendamustine remains a major concern. For these patients with vaccine failure, in addition to the incentive of relatives to get vaccinated and the drastic maintenance of social protection measures, repeated immune stimulation with a fourth vaccine dose, a multimodal immune stimulation with heterologous prime-boost vaccination, or a maximized immune stimulation double-dose approach should be considered (20) . All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; Table 1 : Characteristics of patients included in this study, before and after dose 3 (same data). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; Vaccine Anti-CD20 Mab IgG-anti-S (UI/ml) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted July 22, 2021. ; https://doi.org/10.1101/2021.07.18.21260669 doi: medRxiv preprint Analyses of Risk, Racial Disparity, and Outcomes Among US Patients with Cancer and COVID-19 Infection Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors High seroconversion rate but low antibody titers after two injections of BNT162b2 (Pfizer-BioNTech) vaccine in patients treated with chemotherapy for solid cancers Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity Study of the SARS-CoV-2-specific immune T-cell responses in COVID-19-positive cancer patients Prolonged in-hospital stay and higher mortality after Covid-19 among patients with non-Hodgkin lymphoma treated with B-cell depleting immunotherapy Severe COVID-19 in patients with hematological cancers presenting with viremia Antibody titers against SARS-CoV-2 decline Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection Current perspectives for SARS-CoV-2 vaccination efficacy improvement in patients with active treatment against cancer